Cytotoxicity and subcellular localization of boronated phenanthridinium analogues

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Boronated compounds are investigated for potential therapeutic applications.
• Phenanthridinium analogues have shown DNA intercalating properties.

Purpose of the Study:

• To evaluate the in vitro binding and toxicity of novel boronated phenanthridinium analogues in human malignant glioma cells.
• To investigate the cellular uptake and localization of these compounds.

Main Methods:

• In vitro exposure of cultured human malignant glioma cells to varying concentrations of four boronated phenanthridinium analogues (5-o-CP, 5-p-CP, 5-n-CP, 6-n-CP) for 2 or 24 hours.
• Assessment of cell viability and toxicity.
• Quantification of intracellular boron accumulation using subcellular boron determination.
• Fluorescence microscopy to visualize compound localization in viable and acetone-treated cells.
• In vitro DNA intercalation studies using calf thymus DNA.

Main Results:

• Compounds exhibited dose-dependent toxicity with a narrow therapeutic window; 5-p-CP was most potent, causing cell death at 5 µg/ml.
• No toxicity was observed at 1 µg/ml, yet significant boron accumulation (>100-fold) occurred in viable cells.
• Acetone-treated cells showed lower boron accumulation (~1/4) and nuclear localization, unlike viable cells with broader binding.
• Fluorescence imaging confirmed nuclear uptake in permeabilized cells, but non-nuclear binding in viable cells.
• All compounds demonstrated DNA intercalation in cell-free systems.

Conclusions:

• Boronated phenanthridinium analogues intercalate into DNA but exhibit differential cellular behavior in viable glioma cells.
• The lipophilicity of these compounds may lead to trapping within cellular membranes, hindering nuclear DNA access.
• Further research is needed to optimize delivery and overcome membrane barriers for potential therapeutic efficacy.